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98 The Journal of Thoracic and Cardiobjective: Oxidative stress might be an important factor contributing to injury
uring alloimmune activation. Herein, we evaluated the efficacy of a superoxide
ismutase mimetic, manganese (III) tetrakis (1-methyl-4-pyridyl) porphyrin penta-
hloride (MnTmPyP), on cytokine gene expression and apoptotic signaling in a rat
odel of cardiac transplantation.
ethods: Lewis¡Lewis (isografts) or Wistar-Furth¡Lewis (allografts) heterotopic
at transplants without and with treatment with MnTmPyP were used. Reactive
xygen formation was determined on the basis of dihydroethidine fluorescence and
ucigenin-enhanced chemiluminescence. In situ graft function was determined by
eans of sonomicrometry. Inflammatory cytokine, proapoptotic, and antiapoptotic
ene expression at either postoperative day 4 (early rejection) or postoperative day
(late rejection) was determined by means of reverse transcriptase polymerase
hain reaction.
esults: An increased production of reactive oxygen in allografts was inhibited to
sograft control levels by MnTmPyP. MnTmPyP restored either the percentage of
ractional shortening, the distended diastolic and systolic myocardial segment
engths, or both in allografts. Of the increases in cytokine and proapoptotic gene
xpression in allografts, only interleukin 6 was decreased by MnTmPyP. MnTmPyP
nhibited antiapoptotic gene expression (Bcl-2 and Bcl-xL) during early rejection
ut restored expression at later stages. The increase in activated caspase-3 levels in
llografts was inhibited by MnTmPyP.
onclusions: The mechanism of the beneficial effect of MnTmPyP on graft function
ppear related, in part, to scavenging O2● and by decreasing apoptotic signaling
ather than an effect on inflammatory cytokine gene expression.
rgan transplant rejection, including cardiac allograft rejection, is asso-
ciated with inflammation and alloimmune activation. It is generally
acknowledged that this is associated with enhanced oxidative stress,
lthough there has been no direct determination of reactive oxygen species
roduction in cardiac allograft rejection. Thus counteracting the effects of
xidative stress might prove to be an important mechanism of protecting tissue
rafts during the inflammatory response in cardiac transplants. In this context we
ave determined that diverse antioxidants, such as ascorbic acid, dimethylthio-
rea, or pyrrolidine dithiocarbamate, limit rejection, prolong graft survival, or
oth.1-3 These data suggest that reactive oxygen species play a role in 
ardiac rejection.
Previously, we reported that total superoxide dismutase (SOD) content in rat
ardiac transplants was decreased before graft failure,4 confirming observations
hat the loss in antioxidant enzymes might be an important contributor to
vascular Surgery ● April 2006
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TXmplification of oxidative stress and thus graft rejecti5
e have recently discovered that this decrease is partly
ue to the nitration and inactivation of the manganese
OD (MnSOD) isoform.6
Previous attempts to improve cardiac graft survival by
eans of exogenous administration of SOD protein have
een shown to be ineffective.7 This might be related 
he limited cellular accessibility, dosage, short half-life, and
mmunogenicity of large extracellularly administered pro-
eins. As an alternative to this approach, nonpeptide and
ell-permeable SOD mimetics have been developed, includ-
ng salen, macrocyclic, and metalloporphyrin-based de-
igns. Thus it is anticipated that these agents might circum-
ent the limitations of treatment regimens with SOD
rotein. In this context macrocylcic8-11 or metalloporphy-
inic12 SOD mimetics have been shown to provide pro-
ion in inflammatory disorders, such as carrageenin-induced
nflammation, colitis, and septic shock.
Studies showing efficacy of these compounds in trans-
lant models is extraordinarily rare. One study showed
hat a single injection of the macrocyclic SOD mimetic
40401 before revascularization decreased the extent of
evelopment of coronary artery disease in rat cardiac
llografts,13 which suggests that reactive oxygen spec
lay a role in reperfusion injury in cardiac allografts. To
ate, there are no studies determining the potential effi-
acy of SOD mimetics on alloimmune activation and
raft function in any model of organ rejection and espe-
ially not for cardiac allografts. In the present study we
xamined whether continuous daily treatment of post-
ransplantation recipients with the SOD mimetic manga-
ese (III) tetrakis (1-methyl-4-pyridyl) porphyrin penta-
hloride (MnTmPyP) provided protection in acute
ardiac allograft rejection. We determined efficacy on the
Abbreviations and Acronyms
FasL  Fas ligand
IFN-  interferon 
IL  interleukin
iNOS  inducible nitric oxide synthase
MnSOD manganese superoxide dismutase
MnTBAP Manganese (III) tetrakis(4-benzoic acid)
porphyrin chloride
MnTmPyPManganese (III) tetrakis(1-methyl-4-
pyridyl) porphyrin pentachloride
NO  nitric oxide
POD  postoperative day
RT-PCR  reverse transcriptase polymerase chain
reaction
SOD  superoxide dismutase
TNF-  tumor necrosis factor asis of measures of graft function, as well as inflamma- n
The Journal of Thoracicory cytokine and proapoptotic and antiapoptotic gene
xpression.
ethods
ransplantation and Treatment
ll animal procedures were approved by the local institutional
nimal care and use committee. All animals received humane care
n compliance with the “Guide for the Care and Use of Laboratory
nimals.” Lewis (Lew:RT11) and Wistar-Furth (WF:RT1u) rat
trains were chosen for genetic disparity at both the major and
inor histocompatibility loci for donor-to-recipient combination
f Lewis¡Lewis (for isografts) or Wistar-Furth¡Lewis (for
llografts) rats. Isogeneic and allogeneic heterotopic cardiac
ransplantation was performed under sterile conditions, as previ-
usly described.4 Donor hearts were arrested in cold University
isconsin preservation solution and transplanted to recipients.
otal cold ischemic time was less than 35 minutes for all experi-
ental groups. To test the principle of action of MnTmPyP on
2
● production, some allograft recipients received daily intraperi-
oneal injections of 10 mg/kg MnTmPyP beginning the day of the
peration after transplantation and continuing until postoperative
ay (POD) 4 or 6. This is a dose that has been used primarily in
odent models of acute inflammation by using a single-injection
trategy. In subsequent studies we also evaluated a lower dose of
mg/kg in some of the allograft recipients to determine a dose
esponse on measures of graft function and cytokine and apoptotic
ene expression. During the experimental period, there was no
cute loss of grafts in any group. At POD4 and POD6, grafts were
rrested and flushed with cold University of Wisconsin solution
nd minced, and portions were either frozen in liquid N2 and
tored at 80°C for reverse transcriptase polymerase chain reac-
ion (RT-PCR) and caspase-3 activity assays or used immediately
or assay of reactive oxygen production by using lucigenin-
nhanced chemiluminescence assays.
raft Function
raft function was quantitated in situ by using sonomicrometry
Sonometrics Corp, London, Ontario, Canada) before arrest and
arvesting of tissue for various analyses (described below). In
reliminary studies (unpublished) we found that there were no
ignificant differences in heart rates, segment lengths, or per-
entages of segment shortening between isografts and allografts
hrough POD4, thereby eliminating any possible differences in
unction caused by rat strains. Thus all analyses for this study
ere performed at POD6 for each group (n  6 each). Recipient
ats were anesthetized with pentobarbital (50 mg/kg adminis-
ered intraperitoneally), and 2 piezoelectric crystals were placed
t the midheart level to determine short-axis dimension– graft
unction, as previously reported.14
etection of Reactive Oxygen Species by Using
ihydroethidine Fluorescence
eparin (150 U/kg administered intraperitoneally) was admin-
stered to animals (n  4 each), followed by induction of
nesthesia with sodium pentobarbital (50 mg/kg administered
ntraperitoneally). Transplanted hearts were removed and
laced in 4°C Krebs-Henseleit buffer, and the aorta was can-
ulated for ex vivo perfusion. Hearts were perfused retro-
and Cardiovascular Surgery ● Volume 131, Number 4 899
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TXradely with bicarbonate buffer at a constant pressure for 10
inutes to wash out blood and then perfused for 20 minutes
ith buffer containing 10 mol/L hydroethidine to detect re-
ctive oxygen species production, as previously described in
ur laboratories.15 Because of this intervention, these hea
ould not be used for biochemical and RT-PCR analysis.
At the end of the perfusion, hearts were frozen in OCT 4583
nd sectioned. Frozen sections 10 m thick were cut and thaw
ounted on slides. A cover slip was applied to the sections on
he slides, and images were obtained with a digital camera and
Nikon E600 microscope equipped with epifluorescence (ex-
itation, 488 nm; emission, 610 nm). The fluorescence intensity
f nuclei in 40 cells from each section was measured and was
orrected for background fluorescence in nonnuclear regions
ith MetaMorph software (Visitron Systems GmbH, Puchheim,
ermany). Four sections per heart and 3 hearts per group were
tudied. Animals were administered either MnTmPyP or man-
anese (III) tetrakis (4-benzoic acid) porphyrin chloride
nTBAP 1 hour before the hydroethidine staining.
eactive Oxygen Species Detection by Using
ucigenin-enhanced Chemiluminescence
pproximately 100 mg of heart tissue from isografts and allo-
rafts (n 6 each) was homogenized in 10 mL of Krebs-Henseleit
uffer containing 10 mmol/L N-2-hydroxyethylpiperazine-N-2-
thanesulfonic acid (HEPES) similar to that previously described
or cardiac tissue.16 The tubes containing 1 mL of the homoge
r buffer as blank were incubated in the dark either alone or with
00 mol/L MnTmPyP for 30 minutes. Lucigenin-enhanced
hemiluminescence was then measured for 3 minutes in a lumi-
ometer (Berthold Instruments; Autolomat LB 953, Postfach, Ger-
any) after the addition of 20 mol/L lucigenin to each tube. The
ube containing the buffer and lucigenin was read first to calculate
ackground luminescence, and this value was subtracted from each
ubsequent value. A BioRad (Hercules, Calif) protein assay was
erformed for assessment of protein in milligrams per milliliter.
eactive oxygen production was reported as relative light units
mitted per milligram of protein.
lasma Nitric Oxide Metabolites
he nitric oxide (NO) byproducts, nitrate and nitrite, were
easured (n  6 each) by the Griess reaction after conversion
f nitrate to nitrite by using nitrate reductase with a commercial
it (Cayman Chemical, Ann Arbor, Mich).
nflammatory Cytokine and Apoptotic Gene
xpression
otal RNA was purified by using the Promega SV Total RNA
solation System (Promega, Madison, Wis), according to the
anufacturer’s directions. RNA concentration was determined
pectrophotometrically. cDNA was synthesized from 1 g of
otal RNA and oligo(dT) primers by using the Invitrogen Su-
erscript First-Strand Synthesis System for RT-PCR (Invitro-
en, Carlsbad, Calif), according to the manufacturer’s direc-
ions. One microliter of cDNA was mixed with 25 pmol of
pecific sense and antisense primers and Invitrogen PCR Su-
ermix to a volume of 25 L, and the reaction was incubated in
BioRad iCycler (BioRad) under the following conditions: for w
00 The Journal of Thoracic and Cardiovascular Surgery ● Aprinducible nitric oxide synthase (iNOS) and Bcl-2, 94°C (60
econds), 60°C (60 seconds), and 72°C (60 seconds) for 30
ycles; for interferon  (IFN-), interleukin (IL) 6, IL-10, and
umor necrosis factor  (TNF-), 95°C (30 seconds), 60°C (30
econds), and 72°C (60 seconds) for 35 cycles; for Bcl-xL,
5°C (30 seconds), 60°C (30 seconds), and 72°C (60 seconds)
or 37 cycles; and for Fas ligand (FasL), 95°C (60 seconds),
8°C (60 seconds), and 72°C (60 seconds) for 31 cycles.
Ten microliters of the PCR product was resolved by 1%
garose gel electrophoresis. Ethidium bromide–stained specific
ands were visualized under ultraviolet light, and densitometric
nalysis of specific bands were made with the Alpha Imager
Alpha Innotech Corp, San Leandro, Calif) and expressed as a
atio to -actin gene controls.
aspase Activity
aspase-3 activity assay (n 4-6 each group) was performed with
commercial kit purchased from Sigma-Aldrich (St Louis,
o). This assay is based on the hydrolysis of the peptide substrate
cetyl-ASP-Glu-Val-Asp-p-nitroanilide by caspase-3 to release p-
itroaniline, which is measured spectrophotometrically at 405 nm
n a 96-well enzyme-linked immunosorbent assay reader. Caspase
nzyme activity was determined in units of micromoles of p-
itroaniline per minute per milliliter.
ata Analysis
ll values are expressed as means  standard error of the mean.
tatistical analysis was performed with 1-way analysis of vari-
nce with the Student-Newman-Keuls test for multiple compar-
sons of group means or with the Student t test for comparisons
etween 2 group means. Analysis was performed with Graph-
ad InStat software (San Diego, Calif).
esults
eactive Oxygen Species Production
e used 2 methods to determine reactive oxygen species
roduction: dihydroethidine fluorescence microscopy and
ucigenin-enhanced chemiluminescence. For the former,
hese studies were performed at POD4 because poor
erfusion caused by rejection at POD6 limited optimal
erfusion of dye to make this reliable at this time period.
e found increases (P  .05) in fluorescence intensity in
ardiac allografts compared with isografts perfused with
ihydroethidine, suggesting enhanced reactive oxygen
pecies production (Figure 1). Similar to pilot stu
ith the more traditional probe MnTBAP, we found that
uorescence was decreased (P  .01) to background
sograft levels in allograft recipients injected in vivo with
nTmPyP.
In addition, for quantitative purposes, we performed
ucigenin-enhanced chemiluminescence from cardiac homog-
nates derived from grafts at POD6. We found enhanced
hemiluminescence in cardiac allografts compared with
sograft controls (Figure 2). To document that this ch
uminescence technique was specific for O2● production,
e show that the chemiluminescence signal in both
l 2006
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TXsografts and allografts was abolished by MnTmPyP. To
how the effect of scavenging O2● on NO bioactivity, we
easured plasma NO metabolites (n  6 each). We found
hat MnTmPyP increased plasma NO metabolites versus
ntreated allografts (plasma NO: isografts, 13.94  2.19
Figure 1. Effect of MnTmPyP on fluorescence in transp
dihydroethidine. Quantification of pair-matched react
allografts (Allo) and allografts treated daily with MnT
igure 2. Increased lucigenin-enhanced O2
● production in car-
iac homogenates from allografts (Allo) harvested at postopera-
ive day 6 versus isografts (Iso) and blockade by MnTmPyP (n ieach). †P < .025.
The Journal of Thoracicmol/L; allografts, 38.19  3.06 mol/L; MnTmPyP-
reated allografts, 49.73 2.15 mol/L; P .05, treated vs
ntreated). This change occurred independent of any
hanges in iNOS gene expression normalized to -actin
gene ratio in arbitrary densitometry units: isografts, 0.038
0.021; allografts, 0.508  0.406; MnTmPyP-treated al-
ografts, 0.499  0.090). Collectively, these data indicated
hat the increased chemiluminescence arises through O2●
roduction and that MnTmPyP acts to restore NO bioactiv-
ty by decreasing O2● levels in cardiac tissue.
raft Function
sing in situ sonomicrometry in grafts before harvest on
OD6, we noted decreases (P .01) in heart rate of untreated
llografts versus isografts (Figure 3). Furthermore, b
nd-diastolic and end-systolic segment lengths were in-
reased (P  .001), whereas the percentage of fractional
hortening was decreased (P .001) in allografts compared
ith isografts. Treatment with both doses of MnTmPyP
ormalized both end-diastolic and end-systolic lengths to
d hearts perfused ex vivo at postoperative day 4 with
xygen production in isografts (Iso) versus untreated
(n  4 each). *P < .05. ‡P < .01.lante
ive o
mPyPsograft control levels. The lower dose of MnTmPyP also
and Cardiovascular Surgery ● Volume 131, Number 4 901
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9
TXartially improved the percentage of fractional shortening
P  .001 vs untreated allografts).
nflammatory Cytokine and Proapoptotic and
ntiapoptotic Gene Expression
n samples harvested at POD4 and POD6, we found significant
ncreases in inflammatory cytokine gene expression for IFN-
¶¶
¶02 The Journal of Thoracic and Cardiovascular Surgery ● Aprind the TH2 cytokines IL-6 and IL-10 (Figures 4 and
reatment with MnTmPyP caused a decrease in IL-6 but not
L-10 or INF- at POD4. Later, at POD6, MnTmPyP did not
lter any cytokine expression (Figures 4 and 5).
Apoptosis in rejecting cardiac allografts could be influenced
y changes in either proapoptotic or antiapoptotic gene expres-
¶
¶
Figure 3. Effect of MnTmPyP on in situ graft
function determined by means of transverse-
axis sonomicrometry measured on postoper-
ative day 6 (n  6 each). ¶P < .001 and ‡P <
.01 vs allografts. Iso, Isografts; Allo, allo-
grafts; LoM, low-dose MnTmPyP; HiM, high-
dose MnTmPyP.
Figure 4. Densitometry of reverse transcrip-
tase polymerase chain reaction for interferon
 (IFN) gene expressed as a ratio to the
housekeeping gene -actin, showing the ef-
fect of low- and high-dose MnTmPyP (LoM
and HiM) gene expression at postoperative
days (POD) 4 and 6 (isografts [Iso], n  3
each; allografts [Allo] without and with treat-
ment, n  4 each). ¶P< .001 versus isografts.l 2006
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TXion. In untreated allografts, expression of the proapoptotic
enes FasL and TNF- was upregulated at both time points
Figure 6). The antiapoptotic gene Bcl-2 was also upregu
t POD4, although expression of Bcl-xL was unchanged at
ither time point (Figure 7). MnTmPyP did not modulate 
r TNF- expression in cardiac allografts (Figure 6). Surp
ngly, the low dose of MnTmPyP also inhibited the expression
f the antiapoptotic genes Bcl-2 and Bcl-xL only at this time
oint (Figure 7). At the high dose, MnTmPyP did not
ither Bcl-2 or Bcl-xL gene expression (Figure 7).
aspase-3 Activation
e next evaluated caspase-3 activity to determine that
ncreases in proapoptotic gene expression at early time
oints resulted in increased apoptotic functional activity.
igure 5. Densitometry of reverse transcriptase polymerase chain
eaction for TH2 (interleukin [IL] 6 and interleukin 10) cytokine
enes expressed as a ratio to the housekeeping gene -actin,
howing the effect of MnTmPyP on gene expression at postop-
rative days (POD) 4 and 6 (isografts [Iso], n  3 each; allografts
Allo] without and with treatment, n  4 each). *P< .05, ‡P< .01,
nd ¶P < .001 versus isografts; (*)P < .05 versus allografts. LoM,
ow-dose MnTmPyP; HiM, high-dose MnTmPyP.e found that caspase-3 activity was increased (P  .05) d
The Journal of Thoracicr
n allografts compared with isograft controls (Figure 
reatment with MnTmPyP decreased caspase activity to
sograft levels in a dose-dependent manner (Figure 8
iscussion
his study shows, for the first time, that continuous treat-
ent with a cell-permeable SOD mimetic, MnTmPyP, has
eneficial effects on graft function and apoptotic gene ex-
ression in a rat model of acute cardiac transplantation. The
ajor findings are as follows: (1) MnTmPyP was effective
n inhibiting reactive oxygen species production in cardiac
llografts; (2) the low dose was more effective than the high
ose in improving indices of graft function; (3) MnTmPyP
artially decreased IL-6 gene expression but not IL-10
r IFN- expression at the early stages of rejection; (4)
igure 6. Densitometry of reverse transcriptase polymerase chain
eaction for proapoptotic genes expressed as a ratio to the
ousekeeping gene -actin, showing the effect of MnTmPyP on
ene expression at postoperative days (POD) 4 and 6 (isografts
Iso], n  3 each; allografts [Allo] without and with treatment,
 4 each). ¶P < .001 versus isografts. TNF, Tumor necrosis
actor ; FasL, Fas ligand; LoM, low-dose MnTmPyP; HiM, high-
ose MnTmPyP.
and Cardiovascular Surgery ● Volume 131, Number 4 903
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9
TXnTmPyP modulated antiapoptotic gene (Bcl-2 and Bcl-xL)
xpression; and (5) MnTmPyP inhibited caspase-3 activation.
Macrocyclic SOD mimetics have been used with var-
ed results; however, previously reported in vivo studies
ith MnTmPyP were conducted primarily with a single
retreatment strategy before inducing septic shock and
ere not used in any multiple-dosing or chronic treat-
ent regimens. In this context our study is the first
nown application of a continuous daily treatment with a
etalloporphyrin on inflammatory and apoptotic gene
xpression in any transplant model, including cardiac
ransplantation. MnTmPyP has an advantage over the use
f exogenously administered SOD protein in that it is cell
ermeable.10,17 Thus, unlike exogenous SOD protei
nTmPyP can work effectively to dismutate O2●
ntracellularly.
MnTmPyP was effective in blocking reactive oxygen
roduction in allografts, as observed qualitatively by
igure 7. Densitometry of reverse transcriptase polymerase chain
eaction for antiapoptotic genes expressed as a ratio to the
ousekeeping gene -actin, showing the effect of MnTmPyP on
ene expression at postoperative days (POD) 4 and 6 (isografts
Iso], n  3 each; allografts [Allo] without and with treatment, n
4 each). *P < .05 and ‡P< .01 versus isografts; (*)P < .05,Nigh-dose MnTmPyP.
04 The Journal of Thoracic and Cardiovascular Surgery ● Apriuorescence microscopy and quantitatively by lucigenin-
nhanced chemiluminescence. To our knowledge, this is
he first time that either of these 2 techniques has been
sed to document reactive oxygen production in any
xperimental or transplant model. Our findings agree
ith previously published reports indicating that MnT-
PyP effectively inhibits reactive oxygen production in
at cardiomyocytes in response to hypertrophic stimuli.18,19
ur studies do not delineate whether there are some other
nknown O2● scavenging–independent mechanisms of ac-
ion of MnTmPyP.
In our study we showed a beneficial action of MnT-
PyP on graft function. Although both doses were ef-
ective in reducing the alloimmune-induced increases in
nd-diastolic and end-systolic lengths, only the low dose
as effective in restoring the percentage of segment
hortening. This dose-effect property of this nonpeptide
OD mimetic is reminiscent of the decreased efficacy of
igh doses of exogenous CuZn SOD and MnSOD in
schemia-reperfusion injury in isolated and perfused rab-
it or rat hearts.20,21 This effect of high-dose SOD prote
as not attributed to adverse actions through a peroxi-
ase function of SOD but rather to the fact that that
xcess scavenging of O2● by the high-dose SOD elimi-
ates the beneficial action of O2●, acting at the step to
erminate lipid peroxidation. This biphasic dose depen-
ency of SOD protein can now be applied to in vivo
ardiac models by using nonpeptide SOD mimetics.
We have recently reported that MnSOD protein and
ctivity is significantly decreased in cardiac allografts
nd that this is at least partly due to nitration of MnSOD
rotein.6 Thus, MnTmPyP might have the potential 
ounteract the loss in this major antioxidant enzyme by
mproving scavenging of O2●, thus preventing the for-
ation of peroxynitrite, a potent nitrating agent and
nducer of apoptosis. In fact, despite a lack of change in
NOS expression, our finding that NO levels are actually
ncreased by MnTmPyP suggests that MnTmPyP protects
igure 8. Inhibition by MnTmPyP of alloimmune-induced in-
rease in caspase-3 activity in allografts (Allo) at postoperative
ay 6 (n  4-6 each group). *P < .05 versus isografts, (*)P < .05
s allografts. Iso, Isografts; LoM, low-dose MnTmPyP; HiM, high-
ose MnTmPyP.‡)P < .01 versus allografts. LoM, Low-dose MnTmPyP; HiM,
O from destruction by O2● in allografts.
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TXLong-term treatment with metalloporphyrinic SOD
imetics might have immunomodulatory activity be-
ause treatment with Mn(III) tetrakis (N-ethylpyri-
inium-2-yl)porphyrin decreased T cell–mediated diabe-
ogenesis with decreased inflammatory cell infiltrate in a
ontransplant model of alloimmunity.22 In our study
reatment with MnTmPyP inhibited IL-6 expression with-
ut any effect on IL-10 expression in the early stages but
ot at the later stages of rejection. High serum IL-6 levels
an be predictive of rejection episodes23-25; however, it 
till not clear whether IL-10 plays a beneficial or a
etrimental role in rejection. Recently, in a model of
ouse cardiac transplantation, it was shown that hepato-
yte growth factor exerts its protective effects by enhanc-
ng the expression of IL-10.26 The effect of the metall-
orphyrinic MnTmPyP in our model is similar to the
nability of M40403, a macrocyclic SOD mimetic, to
odulate serum IL-6 levels while increasing IL-10 levels
n Escherichia coli–mediated septic shock.27 Although it
s clear that IFN- plays a significant role in alloimmune
ctivation, the fact that MnTmPyP did not alter either
L-10 or IFN- expression suggest that MnTmPyP acts
ownstream of inflammatory cytokine gene expression in
ur model of cardiac transplantation.
Upregulation of FasL and TNF- are potential path-
ays for apoptosis during alloimmune activation in trans-
lanted organs. It has also been shown that O2● is
ssential for T-cell receptor–stimulated activation of
asL and subsequent cell death.28 However, our finding
hat MnTmPyP did not affect either TNF- or FasL
xpression suggests that this metalloporphyrin compound
cts distally to FasL or TNF-–mediated apoptosis. This
nding is in contrast with a report using another SOD
imetic, MnTBAP, which inhibited Fas-induced liver
ailure in a mouse model.29
Interestingly, at the early stages of rejection (i.e.,
OD4), MnTmPyP inhibited antiapoptotic gene expres-
ion without altering the increased expression of FasL or
NF-. This result was surprising in light of evidence
hat other metalloporphyrinic SOD mimetics, such as
nTBAP, have been shown to increase Bcl-2 expression
n activated T cells.30 This action of MnSOD mimetics 
ppose apoptosis of activated T cells might explain why
igh-dose MnTmPyP does not enhance graft function
espite the benefits of low-dose MnTmPyP in our study.
n noninflammatory cells like cardiac myocytes, NO-
ediated apoptosis is attenuated by MnTBAP, and this is
ssociated with changes in the proapoptotic versus anti-
poptotic gene ratio of Bax/Bcl-2.31 Thus, the cell typ
ndergoing apoptosis might play a role in determining
hether the SOD mimetics are beneficial.
Proapoptotic Bcl-2 family members (eg, Bax) promotehe cytosolic release of cytochrome c, whereas antiapop-
The Journal of Thoracicotic Bcl-2 family members (eg, Bcl-2 and Bcl-xL) in-
ibit the release of cytochrome c and downstream acti-
ation of caspase-3. In our study there was a dose-
ependent inhibition of caspase-3 activation by
nTmPyP.
Collectively, these data suggest that the benefits of
nTmPyP on cardiac transplants appear to be related more
o the balance of proapoptotic versus antiapoptotic gene
xpression rather than upstream modulation of cytokine
ene expression. The effect of MnTmPyP on apoptotic
ignaling appears to be largely independent of TNF- and
asL gene expression but rather at some downstream
poptotic signaling event.
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